Keywords: santarus, zegerid, better, nab, control, nexium/prevacid, san
Santarus Zegerid: better NAB control than Nexium/Prevacid
Article | 29 May 2006
San Diego, USA-based Santarus, a drugmaker focused on gastrointestinal disorders, presented strong clinical data on its proton pump inhibitor, Zegerid ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
